BB's Stock Haven

[Supernova12]

TELEMEDICINE NEWS OUT!! $CVLB
2020 Revenues Climbing 241% to Record $9.2 Million; Raises 2020 Outlook to $40 Million+
Conversion Labs Reports Preliminary Q2
8:44 AM ET 7/7/20 | GlobeNewswire

Conversion Labs Reports Preliminary Q2 2020 Revenues Climbing 241% to Record $9.2 Million; Raises 2020 Outlook to $40 Million+

NEW YORK, July 07, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported preliminary unaudited results for its second quarter ended June 30, 2020. Revenues totaled approximately $9.2 million, up 114% sequentially and up 241% from the same year-ago quarter.

"These record results were driven by strong customer acquisitions and growth in subscription revenue generated by our expanding portfolio of telemedicine, online pharmacy, and wellness brands," said CEO of Conversion Labs, Justin Schreiber.

Conversion Labs CFO, Juan Manuel Piñeiro Dagnery, commented: "This acceleration in top line performance is supporting a significant expansion of our gross margins across our business segments, and demonstrates the strong leverage in our business model. In fact, gross margins for our brands are the strongest they have ever been.

"We continue to see a record number of customers on subscription plans, which is an important metric for our business and indicates a high level of customer satisfaction with our brands. We believe our growing customer retention and lifetime value validates the robustness of our brands and growth strategy."

A major consumer shift to eCommerce and telemedicine during the COVID-19 pandemic has also been supporting the company's rapid growth. The adoption of telemedicine across the healthcare industry has "shifted into hyper-drive" with virtual health care visits on pace to top 1 billion by year end, according to Forrester Research. Another recent report sees the global telemedicine market expanding at a 19.3% compounded annual growth rate, reaching $175 billion by 2026.

Conversion Labs' new cloud-based, end-to-end telemedicine platform, Veritas MD, is supporting the company in addressing this fast growing market with its expanding lineup of telehealth brands. Veritas MD is designed to provide greater access and convenience to the growing number of customers seeking medical treatment and prescription medications from the comfort of their home.

As a result of the company's growth in the first half of the year, management is increasing its full-year 2020 revenue outlook from $36 million to more than $40 million. This compares to revenues of $12.5 million in 2019 and represents growth of more than 220%.

The company expects to report full Q2 results in the second week of August.

About Conversion Labs

Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company's brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.

Important Cautions Regarding Forward-Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may, " "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

Trademarks are the property of their respective owners.

Company Contact

Conversion Labs

Juan Manuel Piñeiro Dagnery

CFO

Email Contact

Media and Investor Relations Contact

Ron Both or Grant Stude

CMA Investor Relations

Tel [phone]

Email Contact

> Dow Jones Newswires

July 07, 2020 08:44 ET (12:44 GMT)

PLEASE READ THE IMPORTANT DISCLOSURES BELOW.
Unless stated otherwise, the web content provided by the E*TRADE family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by E*TRADE Securities LLC or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by E*TRADE Securities LLC or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.
E*TRADE may make available links to other, third party sites or electronic services providers. The material is also being provided to you for educational purposes only unless stated otherwise. The content has been written by a third party not affiliated with E*TRADE or any of its affiliates. E*TRADE and its affiliates are not responsible for the content and the content neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy, sell, or hold any securities.
E*TRADE does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.
Quotes and other information supplied by independent providers identified on the E*TRADE vendor disclosures page

Statement of Financial Condition | About Asset Protection | Customer/User Agreement | Privacy Statement | Business Continuity Plan | Online Security | Contact Us | About Us | About Our Ads

Securities and futures products and services offered by E*TRADE Securities LLC, Member FINRA/SIPC/NFA. Investment advisory services are offered through E*TRADE Capital Management, LLC, a Registered Investment Adviser. Banking products and services are offered by E*TRADE Bank, a Federal savings bank, Member FDIC, or its subsidiaries. E*TRADE Securities LLC, E*TRADE Capital Management, LLC and E*TRADE Bank are separated but affiliated companies.

System response and account access times may vary due to a variety of factors, including trading volumes, market conditions, system performance, and other factors.

© 2020 E*TRADE Financial Corporation